search icon

    Market Snapshot

    blog search icon

    Kinnate Biopharma Inc. Stock Investors, Shareholders, Insiders and Outstanding Shares

    Kinnate Biopharma Inc.

    (NASDAQ:KNTE)

    $7.32

    0.18 (2.52%)

    At Close: 4:00 PM

    Shares & ShareHolders

    Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.

    Shares Outstanding

    44.15 Million

    Float

    43.94 Million

    Shortable

    Yes

    optionable

    Yes

    Shares Short

    3.51 Million

    Short % of shares outstanding

    7.94%

    Shares Short (Prior Month)

    3.49 Million

    2.87%

    Short of Float

    7.94%

    Short % of Shares Outstanding

    Top Institutional Holders

    A total of 0.40% of KNTE shares are owned by insiders. About 98.90% of KNTE shares are held by financial institutions. RA Capital Management LP is the top corporate investor, holding 4.26 Million shares valued at $26.01 Million. A 9.65% stake in Kinnate Biopharma Inc. is owned by the company. Fidelity Management & Research Co owns 2.42 Million shares valued at $14.79 Million, which translates its holding of 5.49% of the stake in the company.

    Holder% StakeShares HeldTotal Value ($)Shares% Change in Portfolio
    RA Capital Management LP9.65% 4,264,14426,011,27800%
    Fidelity Management & Research Co5.49% 2,424,33214,788,425236,78610.82%
    Lynx1 Capital Management LP5.01% 2,213,17813,500,386538,50132.16%
    Viking Global Investors LP4.12% 1,820,46211,104,81800%
    BlackRock Fund Advisors3.80% 1,677,33710,231,756-31,878-1.87%
    Avidity Partners Management LP2.75% 1,212,6117,396,9271,212,611-
    Citadel Advisors LLC2.37% 1,046,0506,380,905-49,811-4.55%
    The Vanguard Group, Inc2.24% 989,4626,035,71815,1861.56%
    Rock Springs Capital Management L1.69% 746,9734,556,535128,58920.79%
    Woodline Partners LP1.19% 524,6693,200,481264,393101.58%

    Kinnate Biopharma Inc. Insiders

    Among the KNTE insiders holding of 0.07% of the stake in company, GORDON CARL L, Director, holds the largest shares of 3,509,030. WILLIAMS RICHARD THOMAS, Chief Medical Officer, is the second largest KNTE insider with ownership of 42,333 shares. N/A,N/A, stands third with possession of N/A shares of that stake.

    InsiderDesignationShares Held
    GORDON CARL LDirector3,509,030
    WILLIAMS RICHARD THOMASChief Medical Officer42,333

    Insider Transaction Summary (6 Months)

    SHARES

    TRANS

    PURCHASES

    0

    0

    Sales

    0

    0

    Net ShareN/A

    0

    0

    NO. of Shares Held

    0

    0

    % Net ShareN/A

    -

    0.00%

    Frequently Asked Questions

    icon

    How many institutions own KNTE stock?

    A company's 13F filings with the Securities and Exchange Commission (SEC) provides investors with comprehensive information about institutional ownership in a listed company, a sign of strength in terms of how many institutions have confidence in that company. The number of institutional investors who currently own KNTE shares is 129, representing 98.90% of the company's common stock.

    icon

    Who are the major shareholders selling Kinnate Biopharma Inc. stock?

    BlackRock Fund Advisors, in the last quarter, reduced its stake in KNTE by -1.87% restricting it's holding to 1.68 Million shares of worth nearly $10.23 Million. Citadel Advisors LLC also lessened -4.55% of the KNTE shares from its portfolio, reducing its holding to 1.05 Million shares of worth $6.38 Million. N/A also shunned KNTE shares holding by N/A last quarter which brought its holding to 0 shares worth $0.

    icon

    Investors who are buying KNTE stock?

    As per its latest 13F filing, RA Capital Management LP increased its stake in KNTE by 0% in the last quarter. The institutional holder raised its holding to 4.26 Million shares having worth more than $26.01 Million. Fidelity Management & Research Co also added 10.82% more shares of KNTE to its portfolio, raising its holding to 2.42 Million shares of worth $14.79 Million. Lynx1 Capital Management LP also increased its KNTE shares holding by 32.16% which brought its holding to 2.21 Million shares worth $13.5 Million.

    icon

    KNTE's major insiders: who are they?

    The insider with the most stakes in KNTE is GORDON CARL L , a Director at the company. Additionally, KNTE stock is highly held by Chief Medical Officer WILLIAMS RICHARD THOMAS and N/A N/A among others.

    icon

    Did an insider recently sell KNTE stock?

    Company executives, directors, and other insiders own 0.4 percent of Kinnate Biopharma Inc.'s stock. Within the last six months, there have been 0 transaction(s) in which KNTE insiders have sold stock, totaling 0 shares. Insiders that have sold shares include

    icon

    Which insider recently purchased KNTE stock?

    There have been no transaction(s) during the past 6-months in which KNTE insiders have bought stock N/A.

    icon

    How much of KNTE does insiders own?

    Around 176.6 Thousands Kinnate Biopharma Inc. shares are held by insiders, which represents about 0.40% of KNTE Stock.

    icon

    Who is the insider with the largest stake?

    KNTE Director, GORDON CARL L holds the largest portfolio of the company's shares. KNTE shares owned by Levinson total nearly 3.51 Million.

    icon

    Which institution holds the most shares in KNTE?

    RA Capital Management LP is the largest institutional owner in KNTE which holds 4.26 Million shares worth $26.01 Million or 9.65% of the total KNTE shares outstanding followed by Fidelity Management & Research Co with ownership of 2.42 Million shares representing 5.49% of the KNTE ownership. Lynx1 Capital Management LP, Inc is the third largest stakeholder with 2.21 Million shares or 5.01% of the ownership worth more than $13.5 Million.

    icon

    Is Kinnate Biopharma Inc. stock optionable?

    Stock options give the owner the ability but not the obligation to buy or sell a security at a predetermined price and date. Stock options can be classified into two types: puts and calls. A put is a bet on falling stock, and a call is a bet on rising stock. As far as the KNTE is concerned, it is a stock which is optionable.

    icon

    Is there a short position on KNTE's shares?

    Number of KNTE shares short as of 2022-10-13 was 3.51 Million. Shares short is a market sentiment in which investors have sold their shares short in a given stock but have not yet covered them or closed them out.

    icon

    About how many outstanding KNTE shares are there?

    As of today, 44.15 Million shares of KNTE are outstanding.

    icon

    Is there many float in Kinnate Biopharma Inc. stock?

    Float represents the number of tradeable shares in a specific stock. By subtracting restricted and closely-held shares from a firm's total outstanding shares, we can calculate its floating stock. The term "closely-held shares" refers to shares held by employees, major shareholders, and company insiders. At present, KNTE has 43.94 Million shares in float.

    icon

    KNTE short ratio: what is it?

    Short ratio is calculated by dividing the number of short shares, short interest or bets that shareholders will sell short from the average daily volume. A higher ratio indicates longer times needed to repurchase borrowed shares (sold). The short ratio for KNTE was N/A as of 2022-10-13.